Montes-Torres Andrea, Llamas-Velasco Mar, Pérez-Plaza Alejandra, Solano-López Guillermo, Sánchez-Pérez Javier
Department of Dermatology, Hospital Universitario de La Princesa, Diego de León 62, Madrid 28006, Spain.
J Clin Med. 2015 Apr 3;4(4):593-613. doi: 10.3390/jcm4040593.
Atopic dermatitis (AD) is one of the most common chronic inflammatory skin diseases that affect both children and adults with a prevalence of 30% and 10%, respectively. Even though most of patients respond satisfactory to topical anti-inflammatory drugs, about 10% require one or more systemic treatments to achieve good control of their illness. The progressive and increasingly detailed knowledge in the immunopathogenesis of AD has allowed research on new therapeutic targets with very promising results in the field of biological therapy. In this article, we will review the different biological treatments with a focus on novel drugs. Their mechanism of action, current status and results from clinical trials and observational studies will be specified.
特应性皮炎（AD）是最常见的慢性炎症性皮肤病之一，影响儿童和成人，患病率分别为30%和10%。尽管大多数患者对局部抗炎药物反应良好，但约10%的患者需要一种或多种全身治疗才能有效控制病情。对AD免疫发病机制的认识不断深入和细化，使得在生物治疗领域对新治疗靶点的研究取得了非常有前景的成果。在本文中，我们将回顾不同的生物治疗方法，重点关注新型药物。将详细说明它们的作用机制、现状以及临床试验和观察性研究的结果。
